Twitter Facebook LinkedIn YouTube

NanoSphere Health Sciences Inc. (CSE:NSHS) New Listing

Video Platform Video Management Video Solutions Video Player

NanoSphere Health Sciences LLC, a wholly owned operating subsidiary, is a biotechnology firm specializing in the creation of the NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond.

Additional Information:

Company: NanoSphere Health Sciences Inc
Website: http://www.nanospherehealth.com
Stock Symbol: CSE: NSHS
Date Published: Dec 7, 2017
Transcript: Available

Video Transcript:

I’m Samantha Deutscher for Investmentpitch Media

NanoSphere Health Sciences Inc. is the latest new listing on the Canadian Securities Exchange, trading under the symbol “NSHS”, having previously traded on the TSX Venture Exchange as Corazon Gold.

NanoSphere Health Sciences LLC, a wholly owned operating subsidiary, is a biotechnology firm specializing in the creation of the NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond.

The company recently closed a private placement, raising gross proceeds of $5.9 million from the issuance of 11.8 million units at $0.50 per unit.

Each unit consisted of 1 share and 1 warrant, with each warrant exercisable at $0.75 for 24 months, subject to an acceleration clause.

NanoSphere is commercializing its disruptive, next-generation nanoparticle delivery system platforms for cannabis under the brand Evolve Formulas.

Evolve has already launched its acclaimed NanoSerum™ product for the recreational and medical cannabis markets in Colorado, where it is available in 70 accounts.

NanoSphere expects to rapidly partner with manufacturers and operators in several states to license their technology and bring the Evolve brand to new markets throughout the United States, and to build on that success by further introducing new product applications.

David Sutton, President, stated: “NanoSphere’s CSE listing and the completion of the $5.9 million escrow release marks one of what will be many milestones for NanoSphere on its road to revolutionizing not only the way Cannabis is administered, but other substances as well. NanoSerum™ is the first clinically-tested transdermal cannabis product to relieve pain in minutes, and we intend to build on that success by opening new markets for Evolve and developing new applications for NanoSerum™”

The shares are trading at $0.73 and with 96.1 million shares outstanding, the company is capitalized at $70.2 million.

For more information, please visit www.nanospherehealth.com, contact David Sutton, President and COO at 720.520.4283 or email dsutton@nanospherehealth.com.

Investor relations is handled by Victor Goncalves, Executive Vice President, at 204-997-5517 or email vgoncalves@corazonau.com

I’m Samantha Deutscher for Investmentpitch Media